ethanesulfonic acid (5-tert-butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-amide | 294851-11-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: ethanesulfonic acid (5-tert-butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl)-amide
• 英文别名: 1-[5-Tert-butyl-3-(ethylsulfonylamino)-2-methoxyphenyl]-3-[4-[6-(morpholin-4-ylmethyl)pyridin-3-yl]naphthalen-1-yl]urea
• CAS: 294851-11-9
• 化学式: C₃₄H₄₁N₅O₅S
• 分子量: 631.796
• InChiKey: PQHOEPBLRPBZKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  45
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2116245A2

  公开（公告）日：2009-11-11

  The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists and endothelin-antagonists, processes for preparing the compositions and the use thereof as medicament in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes.

  本发明涉及新型药物组合物，该组合物包含至少一种表皮生长因子受体激酶抑制剂和至少另外一种选自β-2模拟物、类固醇、PDE-IV抑制剂、p38 MAP激酶抑制剂、NK1拮抗剂和内皮素拮抗剂的活性化合物；本发明还涉及组合物的制备工艺及其在治疗呼吸道或胃肠道疾病以及关节、皮肤或眼睛炎症性疾病中的用途。